IP Library Granted Patent US 12,364,785
Granted Patent B2
US 12,364,785 · App. 16/945,990 · Granted Jul 22, 2025

Expandable hemostat composed of oxidized cellulose

Inventors: Erez Ilan (Kibbutz Netzer Sereni, IL); Omri Faingold (Rehovot, IL); Tamar Auerbach-Nevo (Rehovot, IL); Tali Negreanu-Gilboa (Givatayim, IL); Hadas Alperin (Tel-Aviv, IL); Yi-Lan Allen Wang (Belle Mead, NJ); Dwayne Looney (Flemington, NJ)
Assignee: Ethicon, Inc.
A61L15/28A61L15/425A61L15/44A61L15/64
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,364,785
App. No.
16/945,990
Granted
Jul 22, 2025
Kind
B2
Abstract

An expandable biodegradable hemostatic matrix comprised of oxidized cellulose, and having a density ranging from about 0.8 to about 1.2 gr/cm 3 is disclosed herein. The matrix may be expandable to at least 3 times its original volume within 4 sec upon contact with an aqueous solution room temperature. Further disclosed are methods for making the hemostatic matrix as well as method of treating a wound.

Claims (13)

1. A biodegradable hemostatic matrix comprising oxidized regenerated cellulose (ORC), wherein said ORC is in the form of a non-woven fabric, said ORC comprising sheets, wherein the sheets are fibrous and packed layered sheets, and wherein said matrix is a compressed tablet or pellet having a density ranging from 0.95 to 1.2 gr/cm 3 , and wherein said compressed tablet or pellet is expandable to at least 3 times its original volume within 4 sec upon contact with an aqueous solution at at-least one temperature between 1 and 40° C.

2. The matrix of claim 1 , being capable of expanding to at least 90% of its maximum expansion capacity within 30 seconds following immersion in an aqueous solution.

3. The matrix of claim 2 , being expandable to 15 to 30 times its original volume within 4 sec upon contact with an aqueous solution at at-least one temperature between 10 and 30° C.

4. The matrix of claim 1 , further comprising one or more additives selected from the group consisting of calcium salt, anti-infective agent, and hemostasis promoting agent.

5. The matrix of claim 1 , further comprising one or more excipients selected from the group consisting of sodium chloride, mannitol, albumin, and sodium acetate.

6. The matrix of claim 1 , wherein the carboxyl content of the ORC ranges from 12% to 21%, by weight, per United States Pharmacopeia (USP) 23-NF18.

7. The matrix of claim 1 , having a pre-expansion total surface area ranging from about 0.5 to about 10 cm 2 .

8. The matrix of claim 1 , produced by compressing an ORC-based material by applying on a surface thereof a pressure ranging from 0.3 to 7 ton/cm 2 .

9. The matrix of claim 1 , wherein the ORC comprises less than 8% water prior to the contact with the aqueous solution.

10. The matrix of claim 1 , being expandable to at least 4 times its original volume within 4 sec upon contact with an aqueous solution at at-least one temperature between 10 and 40° C.

11. The matrix of claim 1 , being expandable to at least 5 times its original volume within 4 sec upon contact with an aqueous solution at at-least one temperature between 10 and 40° C.

12. The matrix of claim 1 , being expandable to 3 to 6 times its original volume within 4 sec upon contact with an aqueous solution at at-least one temperature between 10 and 40° C.

13. A method of treating a wound comprising the step of applying the biodegradable hemostatic matrix of claim 1 onto and/or into the wound of a subject in a need thereof.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 21, 2022
From: OMRIX BIOPHARMACEUTICALS LTD.
To: ETHICON, INC.
Reel/Frame 061163/0716 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 24, 2022
From: ILAN, EREZ; FAINGOLD, OMRI; AUERBACH-NEVO, TAMAR; NEGREANU-GILBOA, TALI; ALPERIN, HADAS
To: OMRIX BIOPHARMACEUTICALS LTD.
Reel/Frame 059997/0963 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 24, 2022
From: WANG, YI-LAN ALLEN; LOONEY, DWAYNE
To: ETHICON, INC.
Reel/Frame 059998/0037 →